Veradigm reported Q4 EPS of $0.07, matching analyst estimates
Revenue reached $147.6M, in line with expectations
Stock is down 5.26% in the last 3 months and 3.92% in the last 12 months
Veradigm has a "good performance" Financial Health score according to InvestingPro
📖 Full Retelling
Veradigm (OTC: MDRX) reported fourth quarter earnings results on February 28, 2026, with both earnings per share and revenue meeting analyst expectations, as the healthcare technology company continues its regular financial reporting to investors. The company announced earnings per share of $0.07 for the quarter, precisely matching the consensus estimate of $0.07, while revenue reached $147.6 million, aligning perfectly with the $147.6 million forecasted by analysts. Following the earnings release, Veradigm's stock closed at $4.50 per share, reflecting the market's reaction to the in-line financial performance.
The company's stock performance has shown some volatility in recent months, with shares declining 5.26% over the past three months and 3.92% over the past twelve months. Despite these declines, Veradigm has experienced mixed sentiment among analysts in the last 90 days, with both positive and negative earnings per share revisions being recorded. According to InvestingPro, Veradigm maintains a "good performance" Financial Health score, indicating the company's overall financial stability despite the recent stock price fluctuations.
Investors and market watchers are now focusing on how Veradigm's consistent earnings performance will impact its future trajectory. The company's ability to meet estimates suggests operational stability, though the downward stock trend may indicate concerns about growth prospects or broader market conditions. As healthcare technology continues to evolve, Veradigm's position in this competitive landscape will likely be a key factor in determining its long-term value for shareholders.
Veradigm Inc. (formerly Allscripts Healthcare Solutions, Inc.) is a publicly traded American company that provides physician practices, hospitals, and other healthcare providers with practice management and electronic health record (EHR) technology. Veradigm also provides products for patient engage...
Total amount of income generated by the sale of goods or services
In accounting, revenue is the total amount of income generated by the sale of goods and services related to the primary operations of a business.
Commercial revenue may also be referred to as sales or as turnover. Some companies receive revenue from interest, royalties, or other fees.
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry U.S., Israel strike Iran; Khamenei reported killed U.S., Israel strike Iran — what is known so far Strategists see only temporary market impact from Iran strikes Bitcoin prices fall below $64,000 after U.S./Israel attack on Iran (South Africa Philippines Nigeria) Veradigm earnings matched, revenue was in line with estimates By Investing.com Earnings Published 02/28/2026, 03:19 PM Veradigm earnings matched, revenue was in line with estimates 0 MDRX 8.89% Investing.com - Veradigm (OTC: MDRX ) reported fourth quarter EPS of $0.07, in line with the analyst estimate of $0.07. Revenue for the quarter came in at $147.6M versus the consensus estimate of $147.6M. Veradigm’s stock price closed at $4.50. It is down -5.26% in the last 3 months and down -3.92% in the last 12 months. Veradigm saw positive EPS revisions and negative EPS revisions in the last 90 days. See Veradigm’s stock price’s past reactions to earnings here . According to InvestingPro , Veradigm’s Financial Health score is " good performance ". Check out Veradigm’s recent earnings performance , and Veradigm’s financials here . Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
